ANI Pharmaceuticals EPS Ratio 2011-2026 | ANIP

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio ANI Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-1.04	0.86	-3.05	-3.4	-1.88	0.51	1.31	-0.09	0.34	1.34	2.61	-0.92	-1.27	-3.15

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.61	-3.4	-0.559

Quarterly EPS Ratio ANI Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.19	0.37	0.7	-1.27	-0.14	0.84	0.46	0.3	0.06	-	-0.55	-0.94	-1.27	-	-0.37	-1.17	0.01	-0.3	0.04	-1.03	-0.59	-0.41	0.32	0.55	0.04	0.46	0.43	0.24	0.19	-0.83	0.41	0.23	0.1	-0.09	0.22	0.1	0.12	0.25	0.4	0.31	0.38	1.85	0.59	-0.21	0.33	-	0.13	-6.03	-	-0.16	-1.3 K	-1.64 K	-0.53	-0.36	-0.73	-0.16	-0.2

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.85	-1.64 K	-55.6

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Aquestive Therapeutics AQST	-0.78	$ 4.14	0.36 %	$ 443 M	USA
Arcturus Therapeutics Holdings ARCT	-2.4	$ 8.41	4.73 %	$ 230 M	Israel
Ardelyx ARDX	-0.26	$ 6.06	1.94 %	$ 1.46 B	USA
argenx SE ARGX	-7.99	$ 752.35	0.79 %	$ 25 B	Niderland
Arcutis Biotherapeutics ARQT	-0.13	$ 23.83	0.85 %	$ 3.03 B	USA
Aytu BioScience AYTU	-2.16	$ 2.65	-1.12 %	$ 16.6 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
BioCardia BCDA	-1.23	$ 1.2	-0.04 %	$ 8 M	USA
BioCryst Pharmaceuticals BCRX	-0.43	$ 9.6	6.37 %	$ 1.98 B	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-13.1	$ 9.48	-3.27 %	$ 613 M	USA
BioVie BIVI	-12.1	$ 1.45	2.09 %	$ 2.14 M	USA
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
BioLineRx Ltd. BLRX	-0.12	$ 2.32	4.98 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	1.82	$ 56.49	1.78 %	$ 10.8 B	USA
BioNTech SE BNTX	42.2	$ 92.3	1.23 %	$ 27.2 B	Germany
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-1.96	-	10.36 %	$ 9.8 M	USA
Anavex Life Sciences Corp. AVXL	-0.54	$ 3.04	1.54 %	$ 259 M	USA
BioXcel Therapeutics BTAI	-5.73	$ 1.16	-2.12 %	$ 14.2 M	USA
Burford Capital Limited BUR	75.3	$ 4.54	9.54 %	$ 683 M	Britain
Cabaletta Bio CABA	-2.1	$ 3.2	7.94 %	$ 322 M	USA
Can-Fite BioPharma Ltd. CANF	-0.01	$ 3.21	4.56 %	$ 6.98 B	Israel
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
Catalyst Biosciences CBIO	0.06	$ 19.97	2.94 %	$ 1.78 B	USA
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Codexis CDXS	-0.5	$ 1.97	7.97 %	$ 172 M	USA
Cerus Corporation CERS	-0.08	$ 1.91	2.42 %	$ 364 M	USA
Cullinan Management CGEM	2.46	$ 15.4	6.72 %	$ 928 M	USA
Coherus BioSciences CHRS	1.43	$ 1.75	0.87 %	$ 205 M	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	0.08	-	-	$ 96.9 B	Britain